+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Anthracycline associated cardiotoxicity in survivors of childhood cancer



Anthracycline associated cardiotoxicity in survivors of childhood cancer



Heart 94(4): 525-533



It is accepted practice to prescribe beta-blockers in order to retard aortic dilatation and prevent aortic dissection and rupture in patients with Marfan syndrome. A critical review of the published pharmacological studies shows this practice to be based on limited evidence.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 020655662

Download citation: RISBibTeXText

PMID: 18347383

DOI: 10.1136/hrt.2007.136093


Related references

Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: an analysis from the cardiac risk factors in childhood cancer survivors study. Pediatric Cardiology 34(4): 826-834, 2013

Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatric Cardiology 32(3): 342-353, 2011

Anthracycline-related cardiotoxicity in childhood cancer survivors. Current Opinion in Cardiology 29(1): 103-112, 2014

Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors. Pediatric Cardiology 36(6): 1112-1119, 2015

Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovascular Toxicology 7(2): 122-128, 2007

Preventing and Treating Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer. Current Cancer Therapy Reviews 8(2): 141-151, 2012

Anthracycline cardiotoxicity in survivors of childhood cancer: Clinical course, protection, and treatment. Progress in Pediatric Cardiology 36(1-2): 11-18, 2014

Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circulation. Cardiovascular Imaging 6(6): 873-880, 2013

Anthracycline cardiotoxicity in long-term survivors of childhood cancer: The light is not at the end of the tunnel. Pediatric Blood and Cancer 48(7): 649-650, 2007

Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. Pediatric Blood and Cancer 62(1): 123-127, 2015

Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. Pediatric Research 39(3): 504-512, 1996

Evaluation of traditional and novel measures of cardiac function to detect anthracycline-induced cardiotoxicity in survivors of childhood cancer. Journal of Cancer Survivorship 8(2): 183-189, 2014

Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography. Echocardiography 35(2): 234-240, 2018

Monitoring Survivors of Childhood AML for Anthracycline Cardiotoxicity. Aap Grand Rounds 18(6): 62-63, 2007

Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?. Pediatric Hematology and Oncology 31(3): 237-252, 2014